Shares of Corium International (NASDAQ:CORI) have been given a consensus rating of “Buy” by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $13.00.
Several brokerages have recently weighed in on CORI. Zacks Investment Research upgraded shares of Corium International from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Thursday, March 22nd. ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. BidaskClub upgraded shares of Corium International from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. HC Wainwright set a $14.00 target price on shares of Corium International and gave the company a “buy” rating in a research report on Wednesday, December 27th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 target price on shares of Corium International in a research report on Tuesday, March 27th.
NASDAQ:CORI opened at $10.67 on Wednesday. Corium International has a 52-week low of $4.04 and a 52-week high of $13.93. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40.
Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $7.48 million. equities analysts expect that Corium International will post -1.47 earnings per share for the current year.
In other news, major shareholder Perceptive Advisors Llc purchased 50,350 shares of Corium International stock in a transaction on Tuesday, January 16th. The shares were purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of Corium International stock in a transaction on Thursday, January 18th. The stock was purchased at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new position in Corium International in the fourth quarter valued at about $123,000. California Public Employees Retirement System acquired a new position in Corium International in the fourth quarter valued at about $310,000. Goldman Sachs Group Inc. boosted its position in Corium International by 126.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 18,416 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Corium International in the fourth quarter valued at about $317,000. Finally, California State Teachers Retirement System acquired a new position in Corium International in the second quarter valued at about $263,000. Hedge funds and other institutional investors own 88.58% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Corium International (CORI) Receives $13.00 Consensus Target Price from Analysts” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/14/corium-international-cori-receives-13-00-consensus-target-price-from-analysts.html.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.